Reply to Pennington, T.E.; Thompson, J.F. Sentinel Node Biopsy in Melanoma Remains a Valuable Clinical Tool. Comment on "Dixon et al. Primary Cutaneous Melanoma-Management in 2024. J. Clin. Med. 2024, 13, 1607"
J Clin Med. 2025 Jan 2;14(1):216.
doi: 10.3390/jcm14010216.
1 Department of Research, Australasian College of Cutaneous Oncology, Docklands, VIC 3008, Australia.
2 Research, American Osteopathic College of Dermatology, Kirksville, MO 63501, USA.
3 Department of Dermatology, University of Tasmania, Launceston, TAS 7005, Australia.
4 Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, 06847 Dessau, Germany.
5 Department of Dermatology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
6 Department of Surgery, Campbell University, Buies Creek, NC 27506, USA.
7 Department of Dermatology, University of Modena and Reggio Emilia, 41121 Modena, Italy.
8 Department of Dermatology, Centro Oncologico ad Alta Tecnologia Diagnostica, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 41121 Reggio Emilia, Italy.
We note with interest the commentary by Pennington and Thompson (P&T) regarding our detailed update on the management of primary cutaneous melanoma in 2024 [...].